Role Of BCG In T1G3 Bladder Transitional Cell Carcinoma (TCC)

Trang chủ » T1g3 Tcc » Role Of BCG In T1G3 Bladder Transitional Cell Carcinoma (TCC)

Có thể bạn quan tâm

Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content Dot gov

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation pubmed logo Search: Search Advanced Clipboard User Guide Save Email Send to
  • Clipboard
  • My Bibliography
  • Collections
  • Citation manager
Display options Display options Format Abstract PubMed PMID

Save citation to file

Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel

Email citation

Subject: 1 selected item: 8664924 - PubMed To: From: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel

Add to Collections

  • Create a new collection
  • Add to an existing collection
Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel

Add to My Bibliography

  • My Bibliography
Unable to load your delegates due to an error Please try again Add Cancel

Your saved search

Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons
  • Yes
  • No
Email: (change) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel

Create a file for external citation management software

Create file Cancel

Your RSS Feed

Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy

Actions

CiteCollectionsAdd to Collections
  • Create a new collection
  • Add to an existing collection
Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an errorPlease try again Add Cancel Display options Display options Format AbstractPubMedPMID

Share

  • Permalink Copy

Page navigation

  • Title & authors
  • Abstract
  • Similar articles
  • Publication types
  • MeSH terms
  • Substances
  • Related information
  • LinkOut - more resources
Title & authors Abstract Similar articles Publication types MeSH terms Substances Related information LinkOut - more resources CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

High grade superficial TCC of the bladder (T1 G3) has an important risk of recurrence and/or progression (40%) after TUR-B and a low survival rate (57% at 3 years, 50% at 10 years). Intravescical treatment with BCG seems to be able to reduce these rates. 64 patients with T1 G3 vescical TCC underwent a "second look" TUR-B. 9/64 patients presented locally advanced tumor (T2-3) or persistent high risk superficial TCC (T1 G3 + Tis) and underwent to early cistectomy. BCG intravescical therapy has been performed in the remaining 55 patients: 10 of them had not been evaluated because local or sistemic toxicity and consequent early interruption of treatment. BCG Pasteur was given weekly at the dose of 75 mg for two cycles of 6 weeks with a rest period of 6 weeks between the two cycles and then monthly for one year and every three months during next two years too. After the first 6 weeks 43/45 patients resulted tumor-free and 2/45 presented persistent Tis: after the second 6 weeks-cycle of BCG, two other patients had evidence of vescical TCC (one T2 G3 and the other T1 G3); all these four patients were submitted to radical cystectomy or radiotherapy. Of the reamining 41 patients, 28 presented had no recurrences, nowadays living and tumor-free; 3 presented local neoplastic progression and dead; relapsed in T1 G2 and are living NED after local chemotherapy. At a mean follow-up of 18 months, the total amount of recurrences is 17/45 (38%), progression rate is 4/45 (8.8%), exitus 5/45 (11%) and living NED are 28/45 (62%). In our opinion local BCG treatment for T1 G3 bladder cancer, after TUR--B, seems to be able to reduce the risk of recurrence and mortality.

PubMed Disclaimer

Similar articles

  • Management of high-risk non-muscle invasive bladder cancer. Brausi M, Olaru V. Brausi M, et al. Minerva Urol Nefrol. 2012 Dec;64(4):255-60. Minerva Urol Nefrol. 2012. PMID: 23288212 Review.
  • [T1G3 transitional cell carcinoma of the bladder: our experience with 44 patients treated with intravesical BCG after TUR]. Hurle R, Graziotti P, Ranieri A, Losa A, Micheli E, Lembo A. Hurle R, et al. Arch Ital Urol Androl. 1996 Feb;68(1):13-6. Arch Ital Urol Androl. 1996. PMID: 8664913 Italian.
  • [T1G3 transitional bladder neoplasms: what to do?]. Marcelli G, Bottanelli A, Scattoni V, Baroni GP, Rovellini P, Sciaraffia G, Toia G. Marcelli G, et al. Arch Ital Urol Androl. 1996 Feb;68(1):67-9. Arch Ital Urol Androl. 1996. PMID: 8664926 Italian.
  • [Conservative treatment of high-risk (T1G3) transitional carcinoma]. Catanzaro F, Torelli F, Catanzaro M, Cappellano F, Pizzoccaro M, Baruffi M, Sironi D, Pozzoli GL. Catanzaro F, et al. Arch Ital Urol Androl. 1996 Feb;68(1):21-4. Arch Ital Urol Androl. 1996. PMID: 8664915 Italian.
  • High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder. Pham HT, Soloway MS. Pham HT, et al. Semin Urol Oncol. 1997 Aug;15(3):147-53. Semin Urol Oncol. 1997. PMID: 9394909 Review.
See all similar articles

Publication types

  • Comparative Study Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • English Abstract Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

MeSH terms

  • Administration, Intravesical Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • BCG Vaccine / administration & dosage* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Carcinoma, Transitional Cell / pathology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Carcinoma, Transitional Cell / surgery Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Carcinoma, Transitional Cell / therapy* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Combined Modality Therapy Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Follow-Up Studies Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Humans Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Immunotherapy Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Middle Aged Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Neoplasm Recurrence, Local Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Time Factors Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Urinary Bladder / pathology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Urinary Bladder Neoplasms / pathology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Urinary Bladder Neoplasms / surgery Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Urinary Bladder Neoplasms / therapy* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

Substances

  • BCG Vaccine Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

Related information

  • Cited in Books
  • MedGen

LinkOut - more resources

  • Other Literature Sources

    • The Lens - Patent Citations Database

  • Medical

    • MedlinePlus Health Information
[x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To
  • Clipboard
  • Email
  • Save
  • My Bibliography
  • Collections
  • Citation Manager
[x]

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Từ khóa » T1g3 Tcc